Clinical Trials Logo

Clinical Trial Summary

This study will examine how real-time functional magnetic resonance imaging (rt-fMRI) feedback can be used to modulate brain activation in the context of smoking cues in order to resist craving. Participants will complete a total of three fMRI scanning sessions with a cue suppression task with or without neurofeedback training (NFT). Participants will be randomized to an active group (active NFT) or a control group (no NFT) during the scanning sessions. At the end of the third session, all participants will complete a validated smoking lapse laboratory paradigm to evaluate effects of NFT on smoking behavior.


Clinical Trial Description

Smoking is the greatest preventable cause of mortality and a significant economic burden. Even with the best available treatments, most smokers relapse within days or weeks after a quit attempt. Nicotine replacement therapy, the most widely used pharmacotherapy, yields end of treatment quit rates of <25% suggesting that managing nicotine withdrawal is not sufficient. A smoker's response to smoking cues is one factor that increases risk of relapse. This study will examine how real-time functional magnetic resonance imaging (rt-fMRI) feedback can be used to modulate brain activation in the context of smoking cues in order to resist craving. First, we will conduct a pilot study in 12 smokers for technical development and to evaluate the feasibility of the proposed study procedures. Participants will complete a total of three fMRI scanning sessions with a cue suppression task with or without neurofeedback training (NFT). Participants will be randomized to an active group (active NFT) or a control group (no NFT) during the scanning sessions. At the end of the third session, all participants will complete a validated smoking lapse laboratory paradigm to evaluate effects of NFT on smoking behavior. Upon successful completion of the technical development phase, we will proceed to a proof-of-concept phase, which will recruit 72 smokers to evaluate the efficacy of NFT for smoking behavior. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03302026
Study type Interventional
Source University of Pennsylvania
Contact
Status Completed
Phase N/A
Start date January 2, 2018
Completion date March 28, 2019

See also
  Status Clinical Trial Phase
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT02511704 - Pharmacokinetics and Acute Effects of Multiple Dose of Nicotine: Electronic Cigarette and Cigarette Phase 1
Completed NCT04568395 - Acute Effects of TCIG vs ECIG in PLWH N/A
Completed NCT03338933 - Neurobiology of Alcohol and Nicotine Co-Addiction
Completed NCT03634839 - Effects of E-cigarette Flavors on Youth TCORS 2.0 Phase 1
Recruiting NCT05515354 - Smoking Cessation and Menstrual Cycle Phase Phase 4
Withdrawn NCT06259630 - Nicotine Virtual Reality Conditioned Place Preference Phase 4
Recruiting NCT06170138 - Study to Assess PK, PD, Nicotine Extraction, Palatability, Subjective Effects of Nicotine Pouches - Daily Nicotine Users N/A
Not yet recruiting NCT05932745 - Effects of Novel E-cigarette Constituents on Adults TCORS 3.0 N/A
Not yet recruiting NCT03264755 - Cortical Excitability and Role of rTMS in Nicotine Use Disorder N/A
Recruiting NCT05766254 - Identify the Optimal TMS Target to Modulate Reward Activity N/A
Completed NCT00330187 - Combined Pharmaco/Behavior Therapy in Adolescent Smokers Phase 2
Completed NCT03635333 - Effects of E-Cigarette Flavors on Adults TCORS 2.0 Phase 1
Completed NCT03438188 - Neural Basis of Eating Behavior in Abstinent Smokers N/A
Completed NCT03194958 - Helping Poor Smokers Quit N/A
Recruiting NCT04432064 - Temporal Interference Neurostimulation and Addiction N/A
Recruiting NCT05181891 - Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking Phase 2
Completed NCT05897242 - A Smartphone Application (ACT on Vaping) for Vaping Cessation in Young Adults N/A
Not yet recruiting NCT05994209 - Testing the Feasibility and Acceptability of Social Media and Digital Therapeutics to Decrease Vaping Behaviors Phase 1
Terminated NCT03352609 - Accelerated rTMS for the Reduction of Nicotine Craving N/A